1. Home
  2. OPK vs DBVT Comparison

OPK vs DBVT Comparison

Compare OPK & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OPKO Health Inc.

OPK

OPKO Health Inc.

HOLD

Current Price

$1.24

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$13.72

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPK
DBVT
Founded
2006
2002
Country
United States
France
Employees
N/A
90
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
948.8M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
OPK
DBVT
Price
$1.24
$13.72
Analyst Decision
Hold
Buy
Analyst Count
3
7
Target Price
$1.60
$32.04
AVG Volume (30 Days)
2.8M
251.2K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
$606,879,000.00
$5,636,000.00
Revenue This Year
N/A
$35.04
Revenue Next Year
$4.24
$2,360.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.77
52 Week Low
$0.98
$8.51
52 Week High
$1.61
$26.19

Technical Indicators

Market Signals
Indicator
OPK
DBVT
Relative Strength Index (RSI) 36.95 34.34
Support Level $1.11 $12.63
Resistance Level $1.25 $14.68
Average True Range (ATR) 0.06 0.80
MACD -0.01 -0.14
Stochastic Oscillator 16.92 14.73

Price Performance

Historical Comparison
OPK
DBVT

About OPK OPKO Health Inc.

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: